Khvaramze Shaverdashvili

University of Pittsburgh Medical Center — United States

Medicine · Health Sciences

8h-index357citations20works2.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(9), Lung Cancer Diagnosis and Treatment(5), Peptidase Inhibition and Analysis(4), Cancer Immunotherapy and Biomarkers(3), Protease and Inhibitor Mechanisms(3)

Publications20 total

Advances in the treatment of <i>KRAS</i><sup><i>G12C</i></sup> mutant non–small cell lung cancer
Cancer·2025· 8 citedOpen Access
Abstract B100: Dietary Intervention in Melanoma Patients Treated with Immune Checkpoint Inhibitors
Cancer Immunology Research·2025
Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated Non-Small Cell Lung Cancer: An ATOMIC Registry Analysis
UNC Libraries·2024Open Access
Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator’s Consortium Registry Analysis
JTO Clinical and Research Reports·2024· 1 citedOpen Access
Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLC
JTO Clinical and Research Reports·2024· 3 citedOpen Access
A phase II clinical trial evaluating the safety and efficacy of durvalumab as first line therapy in advanced and metastatic non-small cell lung cancer patients with Eastern Cooperative Oncology Group performance status of 2
EClinicalMedicine·2023· 7 citedOpen Access
Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolution
npj Precision Oncology·2023· 8 citedOpen Access
Targeting the epidermal growth factor receptor following complete surgical resection in patients with early-stage non-small cell lung cancer
Expert Opinion on Pharmacotherapy·2023
A Phase II Clinical Trial Evaluating the Safety and Efficacy of Durvalumab as First Line Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer Patients with Eastern Cooperative Oncology Group Performance Status of 2
SSRN Electronic Journal·2023Open Access
High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience
JTO Clinical and Research Reports·2022· 38 citedOpen Access
INI-1 (SMARCB1)–Deficient Undifferentiated Sinonasal Carcinoma: Novel Paradigm of Molecular Testing in the Diagnosis and Management of Sinonasal Malignancies
The Oncologist·2020· 21 citedOpen Access
KLF4 activates NFκB signaling and esophageal epithelial inflammation via the Rho-related GTP-binding protein RHOF
PLoS ONE·2019· 29 citedOpen Access
KLF4 transcriptionally activates non-canonical WNT5A to control epithelial stratification
Scientific Reports·2016· 24 citedOpen Access
864 KLF4 Controls Esophageal Epithelial Inflammation and Carcinogenesis via Rho GTPase Activation of NfκB Signaling
Gastroenterology·2016
MT1-MMP dependent repression of the tumor suppressor SPRY4 contributes to MT1-MMP driven melanoma cell motility
Oncotarget·2015· 21 citedOpen Access
MT1-MMP REGULATES MELANOMA METASTASIS THROUGH ACTIVATION OF MMP2/RAC1 AXIS AND INHIBITION OF TUMOR SUPPRESSOR GENE SPRY4
OhioLink ETD Center (Ohio Library and Information Network)·2015Open Access
Notch1 Autoactivation via Transcriptional Regulation of Furin, Which Sustains Notch1 Signaling by Processing Notch1-Activating Proteases ADAM10 and Membrane Type 1 Matrix Metalloproteinase
Molecular and Cellular Biology·2015· 37 citedOpen Access
Abstract B07: Targeting an MT1-MMP/MMP2 axis in melanoma by a novel MT1-MMP/MMP2 inhibitor
Cancer Research·2015
<scp>MT</scp>1‐<scp>MMP</scp>modulates melanoma cell dissemination and metastasis through activation of<scp>MMP</scp>2 and<scp>RAC</scp>1
Pigment Cell & Melanoma Research·2013· 61 cited
Pluripotent factor lin-28 and its homologue lin-28b in epithelial ovarian cancer and their associations with disease outcomes and expression of let-7a and IGF-II
European Journal of Cancer·2009· 99 cited

Frequent Co-authors

Jonathan E. Dowell(5), Keman Zhang(4), Barbara Bedogni(4), Liza C. Villaruz(4), Iman Osman(3), Daniel Weinblatt(3), Jonathan P. Katz(3), Timothy F. Burns(3), William Tompkins(3), Connor B. Grady(3), Wei‐Ting Hwang(3), Krishna Chandrasekhara(3), Fangdi Sun(3), Geoffrey Liu(3), Devalben Patel(3), Jorge J. Nieva(3), Amanda Herrmann(3), Kristen A. Marrone(3), Vincent K. Lam(3), Stephen V. Liu(3)